SynthesisPloS one2014
Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis.BMC cancer · 2019Pooled it
- Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis.Digestive diseases and sciences · 2018Pooled it
- Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Disease markers · 2017Pooled it
- Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.Oncotarget · 2016Pooled it
- Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2016Pooled it
- Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication activity.PloS one · 2024Article
- Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective.Journal of personalized medicine · 2022Review
- Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.Journal of hepatocellular carcinoma · 2022Review
- Guidelines for Prevention and Treatment of Chronic Hepatitis B.Journal of clinical and translational hepatology · 2021Article
- Review
- [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Article
- Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.Journal of hepatology · 2018Review
- Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).Journal of clinical and translational hepatology · 2017Article
- Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.Gut and liver · 2016Article
- Challenges of advanced hepatocellular carcinoma.World journal of gastroenterology · 2016Review
- Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.World journal of gastroenterology · 2016Review
- The arterial tumor enhancement pattern on contrast-enhanced computed tomography is associated with primary cancer death after radiofrequency ablation for small hepatocellular carcinoma.Hepatology international · 2016Article
- Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma.Gastroenterology research and practice · 2016Review
- [The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2015Article
- Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis.Molecular and clinical oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe benefit of nucleot(s)ide analogues (NA) for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment has been widely debated due to the relatively weak evidence. The objective of this systematic review was to evaluate the effect of NA on recurrence and survival after curative treatment of HBV-HCC.
methodsA systematic electronic search was performed. All controlled trials comparing NA versus placebo or no treatment were considered for inclusion. Results were expressed as Hazard Ratio for recurrence and survival with 95% confidence intervals using RevMan 5.2.
resultsWe included 13 trials with 6350 patients. There were significant improvements for recurrence-free survival (HR 0.66, 95% CI 0.54-0.80; p<0.0001) and overall survival (HR 0.56, 95% CI 0.43-0.73; p<0.0001) in the adjuvant NA group compared with the control group. Sensitivity analyses confirmed the robustness of the results. There were no serious adverse effects being reported. Lamivudine resistance was from 28.6% to 37.5% but could be rescued by other types of NA or combination therapy.
conclusionOur study suggested benefits of adjuvant NA therapy following curative treatment of HBV-HCC. Since the great proven efficacy of NA in improving clinical and viral parameters besides HCC, further studies should be focused on broadening the indications for NA therapy after curative treatment of HBV-HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.